Prognostic model for second progression-free survival and overall survival in patients with high-risk metastatic hormone-sensitive prostate cancer treated with abiraterone acetate and androgen deprivation therapy
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.A new prognostic model accurately predicts outcomes for high-risk metastatic hormone-sensitive prostate cancer (mHSPC) patients treated with abiraterone acetate (ABI). This tool aids in personalized treatment selection and clinical trial stratification.
Area Of Science
- Oncology
- Prognostic Modeling
- Prostate Cancer Research
Background
- High-risk metastatic hormone-sensitive prostate cancer (mHSPC) requires accurate prognostic tools.
- Abiraterone acetate (ABI) is a key treatment for mHSPC.
- Predicting treatment response and survival is crucial for patient management.
Purpose Of The Study
- To develop and validate a prognostic risk model for high-risk mHSPC patients receiving upfront abiraterone acetate (ABI).
- Identify independent prognostic factors for second progression-free survival (PFS2).
- Stratify patients into risk groups for improved treatment guidance.
Main Methods
- Retrospective multicenter study of 233 high-risk mHSPC patients treated with upfront ABI.
- External validation using an independent cohort of 282 patients.
- Cox proportional hazards regression and Akaike information criterion used to identify prognostic factors and build the model.
Main Results
- Key prognostic factors identified: ECOG performance status ≥2, Gleason score 5, extent of disease ≥3 or liver metastasis, and LDH >220 U/L.
- Median PFS2 varied significantly across risk groups (not reached, 43, and 16 months).
- The model demonstrated predictive accuracy for PFS2 and overall survival (OS) in both discovery and validation cohorts.
Conclusions
- A validated prognostic model incorporating five clinical factors is effective for high-risk mHSPC patients on ABI.
- The model can enhance patient care, guide treatment decisions, and aid in patient classification for clinical trials.
- This tool offers more precise prognostic information for oncologists and patients.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...